Trexall

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trexall

The medication Trexall is a prescription-only pharmaceutical that acts throughout the entire body, defining it as a systemic treatment. Its core composition features the active compound Methotrexate (MTX), a potent synthetic substance primarily used in tablet form for oral administration.

Property Description
Active ingredient Methotrexate (MTX)
Form Oral Tablet
Pharmacological class Antimetabolite, Immunosuppressant
Common use Foundational therapy for chronic inflammatory conditions
Origin Synthetic compound

What is the Defining Identity and Classification of Trexall?

Trexall belongs to the major pharmacological class of antimetabolites and is officially recognized as a conventional synthetic Disease-Modifying Antirheumatic Drug (csDMARD). Chemically, the active ingredient Methotrexate is a synthetic compound specifically engineered as a folic acid analogue. As an antimetabolite, its function is based on interfering with core cellular metabolic processes, a mechanism clinically recognized for controlling cellular overactivity.

This medication's identity as a DHFR inhibitor is central to its action. Methotrexate is an antifolate that works by inhibiting the enzyme dihydrofolate reductase, which is essential for producing the building blocks needed for DNA synthesis. The specific oral tablet form of Trexall provides a convenient delivery method for the Methotrexate compound.


Composition, Form, and General Purpose

Trexall is manufactured as a single active ingredient product, presented as an oral tablet that is taken by mouth for systemic administration. The tablet contains Methotrexate Sodium along with solid pharmaceutical excipients that form the necessary carrier matrix.

The general purpose of this therapy is to help restore systemic balance by managing cellular and immune overactivity. By acting as an immunosuppressant, the medication helps to control the rapid growth and multiplication of certain cells while simultaneously dampening destructive, chronic inflammation. This dual action secures its role as a cornerstone in therapeutic strategies that require long-term regulation of immune function.

Regulatory References

  1. Methotrexate - StatPearls - NCBI Bookshelf - NIH
  2. Methotrexate: MedlinePlus Drug Information

What side effects are possible with Trexall?

Adverse Reaction Scope

The official safety documents for Trexall (Methotrexate) classify potential effects across several physiological systems and frequency categories. The primary risks relate to the drug's systemic impact on rapidly dividing cells, which requires close monitoring of the blood, liver, lungs, kidneys, and gastrointestinal tract.

Component Regulatory Safety Classification
Frequency Classification Very Common (ge 1/10): Nausea, inflammation of the mouth (stomatitis), and elevations in liver enzymes (transaminases). Common (ge 1/100 to < 1/10): Low white blood cell count (leukopenia), headache, fatigue, diarrhea, rash, and hair loss (alopecia).
System-Organ Classes Effects are noted on the Blood and Lymphatic System, Gastrointestinal Disorders, Hepatobiliary Disorders, Respiratory System, Skin, and Renal System.
Serious Adverse Reactions Regulatory warnings highlight the potential for severe, sometimes fatal, toxicities, including profound bone marrow suppression (myelosuppression), pulmonary toxicity (interstitial pneumonitis), severe hepatotoxicity (fibrosis/cirrhosis), and severe dermatological reactions.
Population-Specific Notes The medication is contraindicated for non-neoplastic diseases in pregnancy due to risks to the fetus. Caution and close monitoring are required for patients with pre-existing renal or hepatic impairment and in older adults.

Safety Constraints

The label defines specific limitations for use and mitigation requirements. Use is restricted in patients with severe, pre-existing organ dysfunction (e.g., severe renal or hepatic impairment) and significant blood disorders. To mitigate common toxicities, the co-administration of folic acid is required when treating conditions like rheumatoid arthritis or psoriasis.

Connection to the Overall Safety Profile

This structured safety information establishes that Methotrexate carries the potential for serious, life-threatening toxicities and therefore requires routine clinical observation and monitoring. The regulatory framework communicates the necessity for vigilance across multiple organ systems and defines specific conditions and patient groups where the medication is restricted or contraindicated.

Overdose and Emergency Response

An overdose of Trexall (Methotrexate) can lead to severe or fatal toxic reactions, primarily affecting the body's fastest-growing cells. The officially documented manifestations of severe toxicity involve the hematopoietic and gastrointestinal systems. Specific signs include myelosuppression (a dangerous decrease in blood cell production, such as leukopenia and pancytopenia) and pronounced gastrointestinal toxicity marked by severe diarrhea, ulcerative stomatitis (mouth sores), and potentially hemorrhagic enteritis or intestinal perforation. Fatal outcomes are officially reported, often associated with administration errors where the intended weekly dose was mistakenly taken daily.

Mandatory Emergency Action

In the event of a suspected overdose or the onset of severe symptoms, seeking immediate medical attention is required. Regulatory documents mandate that the drug be immediately discontinued and urgent care sought for the administration of specific rescue agents. The drug profile lists Leucovorin (calcium folinate) as the primary agent used to counteract toxic effects on normal cells. Glucarpidase is also officially described for use in rapidly reducing plasma Methotrexate levels when clearance is delayed due to impaired renal function.

Supportive management, including adequate hydration and urinary alkalinisation, is essential. Patients with impaired kidney function, pathological fluid accumulations, or elderly patients are noted in regulatory information to be at a higher risk for delayed drug elimination and increased toxicity.

Therapeutic Uses of Trexall

Trexall (Methotrexate) is a systemic therapy generally used for managing severe, chronic disease activity across several key therapeutic areas, and may be part of long-term management and symptomatic relief. It is commonly used for conditions characterized by periods of heightened symptoms.

The medication is commonly used to support treatment, applied across domains where additional symptomatic support is needed, and is used for managing symptom clusters related to pain, swelling, and stiffness in chronic inflammatory joint conditions. The therapeutic applications include severe, active rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (pJIA) in pediatric patients, and severe, disabling psoriasis that is noted as recalcitrant to initial therapies. Additionally, it is relevant for managing specific malignancies, such as Acute Lymphoblastic Leukemia (ALL) and select lymphomas.

“Trexall is applied in clinical settings that involve acute or unstable symptom patterns, playing a role in managing the condition where symptoms are linked to heightened physiological activity.”

This use may offer supportive relief that helps ease the overall symptom burden and assists with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relief for Chronic Joint Inflammation The medication is commonly used to help with the joint pain, swelling, and stiffness associated with long-term autoimmune diseases, contributing to managing the condition's progression.

Eligibility and Restrictions for Use

Who Can and Cannot Use Trexall?

This section defines the officially documented population eligibility and restrictions for Trexall (Methotrexate) as established by regulatory authorities.

Contraindicated Populations (Must Not Use)

Absolute contraindications prevent use of Trexall for non-neoplastic diseases in:

  • Pregnant women and breastfeeding mothers.
  • Patients with severe renal impairment or severe hepatic impairment.
  • Patients with significant pre-existing blood disorders (e.g., leukopenia, thrombocytopenia) or active severe infections.
  • Individuals with a history of severe hypersensitivity to Methotrexate.

Age-Group and Condition Restrictions

The medication is approved for use in adults and children aged 3 years and older for specific chronic inflammatory conditions. Use is not recommended for children under 3 years. Older adults may require careful dose consideration due to potential reduction in organ function.

Use is also restricted and requires close monitoring in patients with pathological fluid accumulation (e.g., pleural effusions, ascites) and mandates effective contraception for both male and female patients of reproductive potential during and after treatment.

What should I know about interactions with other medicines?

Trexall Interactions with other medicines and products

The official interaction profile for Trexall (Methotrexate) is structured around compounds that interfere with its elimination and those that create a risk of combined organ-specific toxicity.


Pharmacokinetic Interference and Exposure

Interactions that inhibit the active renal tubular secretion of Methotrexate, such as Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Penicillins, and specific Sulfonamides, may lead to significantly reduced clearance and elevated Methotrexate plasma concentrations. This reduced clearance pattern is officially noted to carry the risk of severe toxicity. Proton Pump Inhibitors (PPIs) also prolong serum levels via transporter inhibition, contributing to increased exposure.


Additive Toxicity and Restrictions

Co-administration with other Hepatotoxic or Nephrotoxic Products, Myelosuppressive Medicines, and Alcohol may cause combined, additive organ-specific adverse reactions. Regulatory guidance advises against co-administration with Live Vaccines due to the recognized potential for disseminated infection. The combination with Radiotherapy may increase the risk of soft tissue necrosis.


Population and Dietary Notes

Methotrexate elimination is formally documented to be reduced in patients with Impaired Renal Function or those with fluid accumulations such as Ascites or Pleural Effusions. Taking oral Methotrexate concurrently with Food may also delay absorption and decrease the maximum serum concentration.

Mechanism of Action

How Trexall Works


Blocking Essential Building Blocks (Antimetabolite Action)

Trexall works primarily as a folate antagonist, targeting the enzyme Dihydrofolate Reductase (DHFR) to inhibit the metabolism of folic acid. This inhibition reduces the availability of necessary precursors (purines and pyrimidines) required for DNA and RNA synthesis, resulting in cytostasis (inhibition of cell growth) in high-turnover cell populations, including lymphocytes.

️ Modulating Inflammatory Signals (Anti-inflammatory Action)

At the cellular level, Trexall is converted into metabolites (methotrexate polyglutamates) that inhibit the enzyme AICAR Transformylase (ATIC). This inhibition triggers the release of adenosine, a purine signaling molecule. Adenosine then binds to receptors on immune cells, resulting in the downregulation of inflammatory mediators (like cytokines) and inducing a systemic anti-inflammatory modulation.

Cell Entry and Retention Mechanisms

The drug must first be actively transported into the cell via the Reduced Folate Carrier (RFC1). Once inside, it undergoes polyglutamation to form compounds that are efficiently retained. This mechanism of uptake and cellular retention allows the drug to remain active at its intracellular targets for a prolonged period, promoting continuous enzyme inhibition.

Dosage and Administration Information

Official Administration Guidelines for Trexall

Methotrexate, the active compound in Trexall, is a medicine with multiple approved administration routes, although the tablet form is specifically for oral use. Other formulations are approved for intravenous, intramuscular, subcutaneous, and intrathecal routes, depending on the indication.

For chronic inflammatory conditions such as rheumatoid arthritis (RA) and psoriasis, the single, most critical instruction is the weekly intermittent frequency.

Condition Standard Starting Dose (Oral) Maximum Weekly Dose (Oral)
Rheumatoid Arthritis 7.5 mg once weekly Generally not to exceed 20 mg to 25 mg
Psoriasis 10 mg to 25 mg once weekly Generally not to exceed 30 mg
pJIA (Pediatric) 10 mg/m^2 once weekly Dose based on body surface area

The oral dose may be taken as a single weekly amount or divided into three smaller doses taken 12 hours apart, once per week. Administration on consecutive daily schedules is explicitly reserved for select neoplastic diseases and is prohibited for RA or psoriasis. Due to potential absorption delay, the medicine should be taken consistently, and official labels advise on the importance of designating a specific day of the week for administration.

Procedural and Adjustment Rules

Official instructions require the tablet to be swallowed whole and not split or crushed. For populations with reduced renal function, dose adjustment is necessary as the medicine is significantly excreted by the kidneys. The overarching principle for long-term use is to gradually adjust the dose to achieve the optimal response, then reduce the schedule to the lowest possible effective amount and longest interval to maintain control.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Trexall, a brand name for methotrexate, is a conventional synthetic disease-modifying antirheumatic drug (csDMARD) widely studied and established as a first-line treatment for rheumatoid arthritis (RA) and severe psoriasis.

Recent research continues to affirm its efficacy, particularly in RA, where it is often considered the anchor drug. Studies indicate that methotrexate can lead to significant improvements, with approximately 20–30% of early-stage RA patients achieving disease remission according to some measures. While evidence for its use in psoriatic arthritis (PsA) is less abundant, studies suggest it can be an effective monotherapy for some patients, with improvements observed in both joint and skin symptoms.


Key Findings and Study Protocols

Focus Area Key Research Findings
Symptom Improvement Symptomatic response is often noted within three to six weeks of initiation, with the full clinical benefit potentially taking up to 12 weeks of consistent use.
Long-Term Safety Long-term observational studies suggest that the termination rate due to toxicity may be lower compared to some other older DMARDs (e.g., gold salts), supporting its sustained use in chronic conditions.
Personalized Response Research into genetic factors (SNPs) is exploring how individual patient genetics may influence drug metabolism, treatment response, and the risk of adverse effects, guiding future personalized care approaches.

Safety data consistently highlight the need for close monitoring of patients. Common adverse events reported in trials include gastrointestinal upset, fatigue, and elevations in liver enzyme levels, emphasizing the importance of regular blood tests throughout the course of treatment. The use of folic acid supplementation is a standard practice established in clinical protocols to help mitigate some of the potential side effects associated with the drug's mechanism of action.

Key Studies & References

  1. highlights of prescribing information (Trexall Tablets - Methotrexate)
  2. Methotrexate - StatPearls (for safety, elimination, and administration details)

Frequently Asked Questions (FAQ)

Common questions about Trexall (FAQ)

Q: Is Trexall classified as a type of chemotherapy drug?

Methotrexate, the active ingredient in Trexall, is scientifically classified as an antimetabolite, which is a drug category used in chemotherapy. However, the low doses used for chronic inflammatory conditions are substantially different from the high doses used to treat various cancers. The official documents describe its use for both purposes.

Q: Why do official documents emphasize the risk of liver damage with Trexall use?

Official documents place a strong emphasis on liver damage due to the possibility of developing severe and potentially irreversible liver toxicity, such as fibrosis or cirrhosis, particularly with long-term use. The regulatory warnings communicate that this damage may occur even without the typical early signs of abnormal liver enzyme tests.

Q: How often are blood tests required when a patient is on Trexall treatment?

Clinical guidelines often describe monitoring frequency, typically suggesting blood tests every two to four weeks when initiating treatment. This frequency is then often adjusted to every one to three months once the patient is on a stable regimen.

Q: Is Trexall considered an immunosuppressant, and what does that mean?

Yes, Trexall is classified as an immunosuppressant. This means that its function is to lessen or control the intensity of the body’s overall immune response. This action helps to manage the destructive, chronic inflammation that characterizes autoimmune conditions.

Q: Does Trexall affect male fertility or sperm quality?

Official product information states that the drug can cause impairment of fertility, leading to oligospermia (low sperm count) or reduced sperm quality. The official label notes that effective contraception is advised for both male and female patients of reproductive potential.

Q: What kind of infections are patients on Trexall more susceptible to?

Because Trexall acts as an immunosuppressant, official documents indicate an increased risk of serious infections. These infections may include different types of fungal, bacterial, or viral illnesses that could potentially spread throughout the body.

Q: Why does Trexall have a 'Black Box Warning' in the prescribing information?

The highest-level regulatory warning, known as the Boxed Warning, is included because the drug is associated with several potentially life-threatening toxicities. These risks include severe suppression of bone marrow, damage to the liver, lungs, or gastrointestinal tract, and the risk of fetal death if taken during pregnancy.

Q: What are the potential signs of lung problems that may be related to Trexall?

Official safety information notes that pulmonary toxicity (lung problems) may be signaled by certain symptoms. These potential signs include the sudden onset of a persistent dry cough, shortness of breath, fever, or unusual fatigue.

Q: Is Trexall ever prescribed for conditions other than inflammatory disease?

Yes, the active ingredient in Trexall, Methotrexate, is approved by regulatory bodies for use in treating various types of cancer (neoplastic diseases). These include certain forms of acute lymphoblastic leukemia, breast cancer, and specific lymphomas.

Q: What types of professional monitoring are required during Trexall therapy?

The regulatory framework mandates ongoing professional monitoring throughout the course of therapy. This typically involves regular blood tests, which check complete blood counts (CBC), liver function, and kidney function. Monitoring may also include a baseline chest X-ray.

Q: What happens if I forget to take my scheduled weekly dose of Trexall?

Regulatory patient instructions state that the drug is taken on a strict weekly cycle. The official advice for a missed weekly dose is to contact a doctor or pharmacist immediately for specific, non-directive guidance on how to proceed with the fixed schedule.

Q: Are there any common food or dietary restrictions to be aware of while taking Trexall?

Official interaction data indicates that certain substances may interact with the drug. For example, high intake of caffeine may reduce its overall effectiveness, and specific supplements containing salicylates could potentially alter the drug levels in the body.

Q: How long does Trexall typically stay in the body after the last dose?

Pharmacokinetic data for the low doses used in chronic inflammatory conditions indicate that the drug has a relatively short half-life. Most of the active compound is typically eliminated from the body within 16.5 to 55 hours following the last dose.

Q: Can people with a history of stomach ulcers use Trexall?

Regulatory safety information indicates that patients who have pre-existing conditions, such as peptic ulcer disease or ulcerative colitis, are at an elevated risk. They may have a greater chance of experiencing severe adverse reactions affecting the gastrointestinal tract.

Q: Are there any known interactions between Trexall and popular herbal supplements?

Yes, official interaction databases list potential concerns with certain herbal supplements. Some, like St. John's Wort, may increase the risk of sun sensitivity, while others may pose risks by altering how the body handles the drug.

Q: What does it mean if my doctor recommends a ‘low-dose’ of Trexall?

The term 'low-dose' refers to the use of Trexall for autoimmune conditions, where the weekly dose is typically 5 mg to 25 mg. This amount is significantly lower than the regimen used to treat cancer. The low-dose is used to modulate the immune system rather than cause rapid cell death.

Q: What is the risk of developing a serious allergic reaction to Trexall?

Official warnings communicate that there is a potential for serious hypersensitivity reactions, which include severe, life-threatening allergic responses like anaphylaxis. Individuals with a history of severe hypersensitivity to the drug are explicitly prohibited from using it.

Q: Can a patient stop taking Trexall suddenly, or does the treatment need to be tapered?

Clinical data indicates that discontinuing the drug for a month or longer may lead to a temporary increase in disease activity or flares in patients with rheumatoid arthritis. Any decision regarding stopping or altering the treatment schedule is a matter requiring clinical oversight.

Q: Does Trexall affect a person's blood pressure?

Some observational studies documented by research sources suggest that Methotrexate use may be associated with a potential benefit, such as lower blood pressure. However, this is observational data and a clear cause-and-effect relationship has not been formally confirmed in regulatory documents.

Q: Can Trexall treatment be resumed if it was stopped for a short time?

Clinical data indicates that for short breaks in treatment, disease activity generally returns to the pre-discontinuation levels once the medication is restarted. The decision to resume treatment and the timing of the next dose is a matter for a healthcare professional to determine.

Q: What is the likelihood of long-term use leading to resistance to Trexall?

Research summaries suggest that between 30% and 50% of rheumatoid arthritis patients may experience a diminished response or non-response to the drug over long-term use. This reduction in effectiveness is commonly noted in scientific literature as 'resistance.'

How should Trexall be stored and disposed of?

Storage and Disposal of Trexall (Methotrexate Tablets, USP)

The official requirements for storing Trexall are defined by strict environmental and safety parameters. The tablets must be stored at Controlled Room Temperature (CRT), specifically between 20 C to 25 C (68 F to 77 F). The medication must be kept away from light and stored in a tight, light-resistant container with a child-resistant closure. Trexall must always be kept out of the reach of children.

Methotrexate is classified as a cytotoxic drug. Therefore, the official disposal instructions require users to follow applicable special handling and disposal procedures designed for hazardous pharmaceutical waste when discarding unused or expired product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trexall found in:

A-Z Index: